Differential Regulation of Human Blood Dendritic Cell Subsets by IFNs
Overview
Affiliations
Based on the relative expression of CD11c and CD1a, we previously identified subsets of dendritic cells (DCs) or DC precursors in human peripheral blood. A CD1a(+)/CD11c(+) population (CD11c(+) DCs), also called myeloid DCs, is an immediate precursor of Langerhans cells, whereas a CD1a(-)/CD11c(-) population (CD11c(-) DCs), sometimes called lymphoid DCs but better known as plasmacytoid DCs, is composed of type I IFN (IFN-alpha beta)-producing cells. Here, we investigate the effects of IFN-alpha beta and IFN-gamma as well as other cytokines on CD11c(+) and CD11c(-) DC subsets, directly isolated from the peripheral blood, instead of in vitro-generated DCs. IFN-gamma and IFN-alpha, rather than GM-CSF, were the most potent cytokines for enhancing the maturation of CD11c(+) DCs. Incubation of CD11c(+) DCs with IFN-gamma also resulted in increased IL-12 production, and this IL-12 allowed DCs to increase Th1 responses by alloreactive T cells. In contrast, IFN-alpha did not induce IL-12 but, rather, augmented IL-10 production. IFN-alpha-primed matured CD11c(+) DCs induced IL-10-producing regulatory T cells; however, this process was independent of the DC-derived IL-10. On the other hand, IFN-alpha by itself neither matured CD11c(-) DCs nor altered the polarization of responding T cells, although this cytokine was a potent survival factor for CD11c(-) DCs. Unlike IFN-alpha, IL-3 was a potent survival factor and induced the maturation of CD11c(-) DCs. The IL-3-primed CD11c(-) DCs activated T cells to produce IL-10, IFN-gamma, and IL-4. Thus, CD11c(+) and CD11c(-) DC subsets play distinct roles in the cytokine network, especially their responses to IFNs.
Intracellular DNA sensing by neutrophils and amplification of the innate immune response.
Mankan A, Czajka-Francuz P, Prendes M, Ramanan S, Koziej M, Vidal L Front Immunol. 2023; 14:1208137.
PMID: 37483598 PMC: 10361817. DOI: 10.3389/fimmu.2023.1208137.
Su B, Li R, Song F, Liu M, Sun X Aging (Albany NY). 2023; 15(14):6822-6833.
PMID: 37451839 PMC: 10415557. DOI: 10.18632/aging.204874.
Ding N, You A, Yang H, Hu G, Lai C, Liu W Clin Cancer Res. 2023; 29(11):2095-2109.
PMID: 36951687 PMC: 10233356. DOI: 10.1158/1078-0432.CCR-22-3836.
Guerrero-Rodriguez J, Cardenas-Vargas A, Gutierrez-Silerio G, Sobrevilla-Navarro A, Bastidas-Ramirez B, Hernandez-Ortega L Mol Biotechnol. 2021; 64(4):413-423.
PMID: 34687024 DOI: 10.1007/s12033-021-00408-6.
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.
von Locquenghien M, Rozalen C, Celia-Terrassa T J Clin Invest. 2021; 131(1).
PMID: 33393507 PMC: 7773346. DOI: 10.1172/JCI143296.